PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
May 07, 2024 08:30 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a...
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast
April 26, 2024 08:30 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, April 26, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce...
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
April 23, 2024 08:30 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading biopharmaceutical company dedicated to advancing treatments for...
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
April 16, 2024 16:30 ET
|
PaxMedica, Inc.
Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously...
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
April 11, 2024 16:30 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today...
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
March 13, 2024 08:20 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today...
PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data
November 17, 2023 08:00 ET
|
PaxMedica, Inc.
LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN –PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that...
PaxMedica's Chief Medical Officer Discusses FDA Meeting Highlights on The Bell2Bell Podcast
November 09, 2023 08:00 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IBN, a leading communications organization focused on linking public companies to the investment community, has unveiled the latest episode of The...
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)
November 02, 2023 08:30 ET
|
PaxMedica, Inc.
TARRYTOWN, N.Y., Nov. 02, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, has...
PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
October 31, 2023 08:00 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological...